

Supplemental Table 1: Mixed-effects multivariable model evaluating the recipient and donor predictors of MP preservation in SLK (N=5,988)

| | Covariate-adjusted OR (95% CI) | p-value |
|-------------------------------------|-----------------------------------|---------|
| Recipient female sex | 1.20 (0.98-1.47) | 0.072 |
| Recipient age, per year | 1.00 (0.99-1.01) | 0.590 |
| Recipient race/ethnicity | | 0.760 |
| White | Reference | |
| Black | 0.86 (0.64-1.14) | |
| Hispanic | 0.88 (0.66-1.19) | |
| Asian | 0.82 (0.48-1.40) | |
| Other | 1.04 (0.56-1.95) | |
| Native MELD at LT, per point | 1.01 (0.99-1.03) | 0.359 |
| Kidney disease severity | | 0.826 |
| On dialysis | Reference | |
| eGFR <30mL/min/1.73m ² * | 0.94 (0.75-1.17) | |
| eGFR ≥30mL/min/1.73m ² * | 1.02 (0.75-1.38) | |
| Ascites | | 0.503 |
| None | Reference | |
| Mild | 0.84 (0.62-1.13) | |
| Moderate-severe | 0.89 (0.65-1.20) | |
| Encephalopathy | | 0.290 |
| None | Reference | |
| Grade 1-2 | 1.18 (0.92-1.51) | |
| Grade 3-4 | 0.98 (0.68-1.41) | |
| Recipient location | | 0.961 |
| Home | Reference | |
| Inpatient | 1.00 (0.76-1.31) | |
| ICU | 1.04 (0.75-1.45) | |
| Recipient diabetes | 1.02 (0.81-1.29) | 0.867 |
| Recipient kidney disease | | 0.525 |
| Glomerular disease | Reference | |
| Diabetes | 1.02 (0.66-1.56) | |
| Hypertension | 0.92 (0.55-1.51) | |
| Polycystic kidney disease | 1.22 (0.73-2.04) | |
| Hepatorenal syndrome | 0.83 (0.56-1.22) | |
| Other | 0.94 (0.63-1.40) | |
| Donor age, per year | 1.02 (1.01-1.03) | <0.001 |
| Female donor sex | 0.99 (0.81-1.21) | 0.911 |
| Donor race/ethnicity | | 0.249 |
| White | Reference | |
| Black | 1.16 (0.89-1.53) | |
| Hispanic | 1.21 (0.91-1.63) | |
| Asian/other | 0.74 (0.43-1.28) | |
| Donor hypertension | 1.04 (0.81-1.34) | 0.753 |
| Donor diabetes | 1.47 (0.96-2.24) | 0.073 |
| DCD donor | 2.81 (1.88-4.20) | <0.001 |
| Kidney graft CIT, per hour | 1.10 (1.08-1.11) | <0.001 |

| | | |
|---------------------------------------|------------------|--------|
| Split liver | 0.74 (0.32-1.74) | 0.488 |
| Share type | | <0.001 |
| Local | Reference | |
| Regional | 0.47 (0.36-0.61) | |
| National | 0.67 (0.40-1.13) | |
| Donor HCV Ab positive | 1.12 (0.77-1.63) | 0.555 |
| Donor terminal creatinine, per 1mg/dL | 1.22 (1.08-1.39) | 0.001 |
| Donor BMI, per kg/m ² | 1.02 (1.00-1.04) | 0.020 |
| Donor cause of death | | 0.359 |
| Anoxia | Reference | |
| CVA | 0.77 (0.58-1.01) | |
| Head trauma | 0.98 (0.77-1.24) | |
| CNS tumor | 0.64 (0.19-2.18) | |
| Other | 0.83 (0.45-1.52) | |
| Transplant era | | <0.001 |
| 2005-2009 | Reference | |
| 2010-2014 | 2.42 (1.72-3.39) | |
| 2015-2020 | 6.03 (4.30-8.44) | |

Supplemental Table 2: Mixed-effects multivariable logistic regression model evaluating kidney allograft preservation strategy as a predictor of delayed graft function (N=5,986)

| | Covariate-adjusted OR for DGF (95% CI) | p-value |
|--------------------------------------|--|--------------|
| Kidney allograft preservation | | 0.008 |
| Cold storage | Reference | |
| Machine perfusion | 0.74 (0.60-0.92) | |
| Recipient female sex | 1.10 (0.96-1.27) | 0.180 |
| Recipient age, per year | 1.00 (0.99-1.00) | 0.423 |
| Recipient race/ethnicity | | 0.091 |
| White | Reference | |
| Black | 1.22 (0.99-1.51) | |
| Hispanic | 0.95 (0.78-1.16) | |
| Asian | 1.41 (1.00-1.99) | |
| Other | 1.01 (0.61-1.68) | |
| Native MELD at LT, per point | 1.03 (1.02-1.05) | <0.001 |
| Kidney disease severity | | <0.001 |
| On dialysis | Reference | |
| eGFR <30mL/min/1.73m ² * | 0.39 (0.33-0.47) | |
| eGFR ≥30mL/min/1.73m ² * | 0.31 (0.24-0.39) | |
| Ascites | | 0.007 |
| None | Reference | |
| Mild | 0.81 (0.65-1.01) | |
| Moderate-severe | 0.70 (0.56-0.88) | |
| Encephalopathy | | 0.565 |
| None | Reference | |
| Grade 1-2 | 1.10 (0.92-1.32) | |
| Grade 3-4 | 1.09 (0.84-1.41) | |
| Recipient location | | 0.001 |
| Home | Reference | |
| Inpatient | 0.92 (0.75-1.12) | |
| ICU | 1.36 (1.09-1.70) | |
| Recipient diabetes | 0.94 (0.80-1.11) | 0.487 |
| Recipient kidney disease | | 0.229 |
| Glomerular disease | Reference | |
| Diabetes | 1.27 (0.92-1.74) | |
| Hypertension | 1.17 (0.82-1.67) | |
| Polycystic kidney disease | 0.79 (0.52-1.20) | |
| Hepatorenal syndrome | 1.08 (0.81-1.46) | |
| Other | 1.05 (0.78-1.41) | |
| Donor age, per year | 1.01 (1.01-1.02) | <0.001 |
| Female donor sex | 1.04 (0.90-1.22) | 0.601 |
| Donor race/ethnicity | | 0.447 |
| White | Reference | |
| Black | 0.91 (0.74-1.11) | |
| Hispanic | 0.95 (0.78-1.16) | |
| Asian/other | 0.77 (0.55-1.20) | |
| Donor hypertension | 1.35 (1.13-1.61) | 0.001 |
| Donor diabetes | 1.39 (1.03-1.89) | 0.032 |

| | | |
|---------------------------------------|------------------|--------|
| DCD donor | 2.64 (1.98-3.52) | <0.001 |
| Kidney graft CIT, per hour | 1.02 (1.01-1.03) | <0.001 |
| Split liver | 0.65 (0.33-1.28) | 0.211 |
| Share type | | 0.020 |
| Local | Reference | |
| Regional | 1.20 (1.01-1.42) | |
| National | 1.55 (1.03-2.36) | |
| Donor HCV Ab positive | 0.92 (0.69-1.22) | 0.513 |
| Donor terminal creatinine, per 1mg/dL | 1.28 (1.17-1.40) | <0.001 |
| Donor BMI, per kg/m ² | 1.02 (1.01-1.03) | 0.001 |
| Donor cause of death | | 0.077 |
| Anoxia | Reference | |
| CVA | 1.22 (1.00-1.48) | |
| Head trauma | 0.92 (0.77-1.10) | |
| CNS tumor | 0.75 (0.27-2.12) | |
| Other | 1.01 (0.65-1.57) | |
| Transplant era | | <0.001 |
| 2005-2009 | Reference | |
| 2010-2014 | 1.59 (1.28-1.99) | |
| 2015-2020 | 1.96 (1.56-2.46) | |

Supplemental Table 3: Multivariable logistic regression model evaluating center MP use as a predictor of delayed graft function (N=5,986)

| | Covariate-adjusted OR for DGF (95% CI) | p-value |
|--|--|------------------|
| Center MP use, per 10% increase | 0.93 (0.90-0.96) | <0.001 |
| Recipient female sex | 1.07 (0.94-1.23) | 0.299 |
| Recipient age, per year | 1.00 (0.99-1.00) | 0.483 |
| Recipient race/ethnicity | | 0.006 |
| White | Reference | |
| Black | 1.19 (0.98-1.45) | |
| Hispanic | 1.17 (0.99-1.39) | |
| Asian | 1.75 (1.26-1.39) | |
| Other | 1.16 (0.72-1.88) | |
| Native MELD at LT, per point | 1.03 (1.02-1.05) | <0.001 |
| Kidney disease severity | | <0.001 |
| On dialysis | Reference | |
| eGFR <30mL/min/1.73m ² * | 0.36 (0.30-0.42) | |
| eGFR ≥30mL/min/1.73m ² * | 0.32 (0.25-0.40) | |
| Ascites | | 0.004 |
| None | Reference | |
| Mild | 0.79 (0.64-0.96) | |
| Moderate-severe | 0.70 (0.57-0.86) | |
| Encephalopathy | | 0.409 |
| None | Reference | |
| Grade 1-2 | 1.05 (0.89-1.23) | |
| Grade 3-4 | 0.92 (0.73-1.16) | |
| Recipient location | | <0.001 |
| Home | Reference | |
| Inpatient | 0.99 (0.82-.1.19) | |
| ICU | 1.72 (1.40-2.10) | |
| Recipient diabetes | 0.98 (0.84-1.15) | 0.839 |
| Recipient kidney disease | | 0.446 |
| Glomerular disease | Reference | |
| Diabetes | 1.13 (0.84-1.53) | |
| Hypertension | 1.00 (0.71-1.41) | |
| Polycystic kidney disease | 0.85 (0.58-1.26) | |
| Hepatorenal syndrome | 1.12 (0.85-1.49) | |
| Other | 0.97 (0.74-1.29) | |
| Donor age, per year | 1.01 (1.01-1.02) | <0.001 |
| Female donor sex | 1.00 (0.87-1.15) | 0.981 |
| Donor race/ethnicity | | 0.289 |
| White | Reference | |
| Black | 0.88 (0.73-1.07) | |
| Hispanic | 1.11 (0.93-1.33) | |
| Asian/other | 0.97 (0.70-1.34) | |
| Donor hypertension | 1.25 (1.05-1.48) | 0.011 |
| Donor diabetes | 1.41 (1.06-1.89) | 0.018 |
| DCD donor | 2.70 (2.07 (3.51) | <0.001 |
| Kidney graft CIT, per hour | 1.02 (1.01-1.03) | <0.001 |

| | | |
|---------------------------------------|------------------|--------|
| Split liver | 0.80 (0.42-1.54) | 0.505 |
| Share type | | 0.001 |
| Local | Reference | |
| Regional | 1.24 (1.06-1.45) | |
| National | 1.84 (1.25-2.71) | |
| Donor HCV Ab positive | 0.91 (0.70-1.19) | 0.514 |
| Donor terminal creatinine, per 1mg/dL | 1.27 (1.16-1.38) | <0.001 |
| Donor BMI, per kg/m ² | 1.02 (1.01-1.03) | 0.001 |
| Donor cause of death | | 0.057 |
| Anoxia | Reference | |
| CVA | 1.21 (1.01-1.45) | |
| Head trauma | 0.91 (0.78-1.08) | |
| CNS tumor | 0.81 (0.30-2.16) | |
| Other | 0.98 (0.64-1.49) | |
| Transplant era | | <0.001 |
| 2005-2009 | Reference | |
| 2010-2014 | 1.40 (1.14-1.72) | |
| 2015-2020 | 1.63 (1.32-2.01) | |

Supplemental Table 4: Mixed effects multivariable logistic regression model evaluating kidney allograft preservation strategy as a predictor of primary non-function (N=5,776)

| | Covariate-adjusted OR for PNF (95% CI) | p-value |
|--------------------------------------|--|--------------|
| Kidney allograft preservation | | 0.637 |
| Cold storage | Reference | |
| Machine perfusion | 0.88 (0.52-1.49) | |
| Kidney disease severity | | 0.002 |
| On dialysis | Reference | |
| eGFR <30mL/min/1.73m ² * | 0.67 (0.42-1.05) | |
| eGFR ≥30mL/min/1.73m ² * | 0.18 (0.07-0.50) | |
| Recipient location | | 0.011 |
| Home | Reference | |
| Inpatient | 0.79 (0.48-1.30) | |
| ICU | 1.72 (1.11-2.66) | |
| Donor age, per year | 1.03 (1.01-1.04) | <0.001 |
| Donor BMI, per kg/m ² | 1.05 (1.02-1.08) | 0.002 |
| Donor cause of death | | 0.021 |
| Anoxia | Reference | |
| CVA | 2.01 (1.19-3.40) | |
| Head trauma | 1.48 (0.87-2.52) | |
| CNS tumor | 6.06 (1.66-22.08) | |
| Other | 1.66 (0.49-5.69) | |

Supplemental Table 5: Multivariable logistic regression model evaluating center MP use as a predictor of delayed graft function (N=5,986)

| | Covariate-adjusted OR for DGF (95% CI) | p-value |
|--|--|--------------|
| Center MP use, per 10% increase | 0.94 (0.85-1.04) | 0.233 |
| Kidney disease severity | | 0.002 |
| On dialysis | Reference | |
| eGFR <30mL/min/1.73m ² * | 0.67 (0.43-1.05) | |
| eGFR ≥30mL/min/1.73m ² * | 0.18 (0.07-0.50) | |
| Recipient location | | 0.012 |
| Home | Reference | |
| Inpatient | 0.79 (0.48-1.30) | |
| ICU | 1.72 (1.11-2.66) | |
| Donor age, per year | 1.03 (1.01-1.04) | <0.001 |
| Donor BMI, per kg/m ² | 1.05 (1.02-1.08) | 0.002 |
| Donor cause of death | | 0.021 |
| Anoxia | Reference | |
| CVA | 2.01 (1.19-3.39) | |
| Head trauma | 1.48 (0.87-2.52) | |
| CNS tumor | 6.11 (1.68-22.2) | |
| Other | 1.65 (0.48-5.64) | |

Note: Likelihood ratio test for mixed-effects versus standard logistic regression p=0.074

Supplemental Table 6: Multivariable Cox proportional hazards model evaluating kidney allograft preservation strategy as a predictor of kidney graft survival (N=5,928)

| | Covariate-adjusted HR for graft survival (95% CI) | p-value |
|--------------------------------------|---|--------------|
| Kidney allograft preservation | | 0.230 |
| Cold storage | Reference | |
| Machine perfusion | 0.91 (0.78-1.06) | |
| Recipient female sex | 0.93 (0.83-1.03) | 0.167 |
| Recipient age, per year | 1.01 (1.00-1.02) | <0.001 |
| Recipient race/ethnicity | | 0.001 |
| White | Reference | |
| Black | 1.19 (1.03-1.37) | |
| Hispanic | 0.83 (0.72-0.96) | |
| Asian | 1.01 (0.78-1.31) | |
| Other | 0.55 (0.33-0.93) | |
| Native MELD at LT, per point | 1.00 (0.99-1.01) | 0.549 |
| Kidney disease severity | | 0.003 |
| On dialysis | Reference | |
| eGFR <30mL/min/1.73m ² * | 0.84 (0.75-0.95) | |
| eGFR ≥30mL/min/1.73m ² * | 0.81 (0.69-0.96) | |
| Ascites | | 0.208 |
| None | Reference | |
| Mild | 0.98 (0.84-1.17) | |
| Moderate-severe | 0.90 (0.76-1.06) | |
| Encephalopathy | | 0.136 |
| None | Reference | |
| Grade 1-2 | 1.03 (0.90-1.17) | |
| Grade 3-4 | 1.19 (0.99-1.43) | |
| Recipient location | | 0.012 |
| Home | Reference | |
| Inpatient | 1.08 (0.94-1.25) | |
| ICU | 1.28 (1.09-1.51) | |
| Recipient diabetes | 1.23 (1.09-1.51) | 0.001 |
| Recipient kidney disease | | 0.001 |
| Glomerular disease | Reference | |
| Diabetes | 1.17 (0.94-1.45) | |
| Hypertension | 1.20 (0.94-1.52) | |
| Polycystic kidney disease | 0.63 (0.44-0.88) | |
| Hepatorenal syndrome | 0.95 (0.76-1.19) | |
| Other | 1.10 (0.90-1.35) | |
| Donor age, per year | 1.01 (1.01-1.02) | <0.001 |
| Female donor sex | 1.03 (0.92-1.14) | 0.620 |
| Donor race/ethnicity | | 0.073 |
| White | Reference | |
| Black | 1.19 (1.04-1.37) | |
| Hispanic | 1.09 (0.94-1.26) | |
| Asian/other | 1.13 (0.87-1.46) | |
| Donor hypertension | 1.17 (1.03-1.33) | 0.017 |
| Donor diabetes | 1.05 (0.84-1.33) | 0.660 |

| | | |
|---------------------------------------|------------------|--------|
| DCD donor | 1.51 (1.21-1.88) | <0.001 |
| Kidney graft CIT, per hour | 1.01 (1.00-1.01) | 0.069 |
| Split liver | 1.18 (0.74-1.87) | 0.489 |
| Share type | | 0.011 |
| Local | Reference | |
| Regional | 1.19 (1.04-1.35) | |
| National | 1.38 (0.98-1.94) | |
| Donor HCV Ab positive | 0.93 (0.74-1.17) | 0.517 |
| Donor terminal creatinine, per 1mg/dL | 1.03 (0.97-1.09) | 0.307 |
| Donor BMI, per kg/m ² | 1.00 (0.99-1.01) | 0.422 |
| Donor cause of death | | 0.446 |
| Anoxia | Reference | |
| CVA | 1.02 (0.88-1.18) | |
| Head trauma | 0.96 (0.84-1.10) | |
| CNS tumor | 1.28 (0.76-2.17) | |
| Other | 0.76 (0.53-1.10) | |
| Transplant era | | <0.001 |
| 2005-2009 | Reference | |
| 2010-2014 | 0.79 (0.70-0.90) | |
| 2015-2020 | 0.75 (0.64-0.89) | |

Supplemental Table 7: Multivariable Cox proportional hazards model evaluating kidney allograft preservation strategy as a predictor of kidney graft survival inclusive of the interaction with KDPI category (N=5,928)

| | Covariate-adjusted HR for graft survival (95% CI) | p-value |
|--|---|------------------|
| Kidney allograft preservation | | 0.014 |
| Cold storage | Reference | |
| Machine perfusion (at KDPI <20%) | 0.67 (0.49-0.92) | |
| KDPI category (cold storage preservation) | | <0.001 |
| <20% | Reference | |
| 20-34% | 1.03 (0.88-1.21) | |
| 35-85% | 1.45 (1.28-1.65) | |
| >85% | 1.90 (1.49-2.42) | |
| Allograft preservation * KDPI category | | 0.029 |
| Machine perfusion * KDPI <20% | Reference | |
| Machine perfusion * KDPI 20-34% | 1.35 (0.86-2.13) | |
| Machine perfusion * KDPI 35-85% | 1.59 (1.10-2.29) | |
| Machine perfusion * KDPI >85% | 2.11 (1.21-3.67) | |
| Recipient female sex | 0.91 (0.82-1.01) | 0.088 |
| Recipient age, per year | 1.01 (1.01-1.02) | <0.001 |
| Recipient race/ethnicity | | 0.001 |
| White | Reference | |
| Black | 1.16 (1.01-1.34) | |
| Hispanic | 0.83 (0.72-0.96) | |
| Asian | 1.01 (0.79-1.31) | |
| Other | 0.54 (0.33-0.91) | |
| Native MELD at LT, per point | 1.00 (0.99-1.01) | 0.666 |
| Kidney disease severity | | 0.003 |
| On dialysis | Reference | |
| eGFR <30mL/min/1.73m ² * | 0.84 (0.75-0.95) | |
| eGFR ≥30mL/min/1.73m ² * | 0.81 (0.69-0.95) | |
| Ascites | | 0.322 |
| None | Reference | |
| Mild | 0.99 (0.84-1.16) | |
| Moderate-severe | 0.91 (0.77-1.08) | |
| Encephalopathy | | 0.276 |
| None | Reference | |
| Grade 1-2 | 1.03 (0.91-1.17) | |
| Grade 3-4 | 1.15 (0.96-1.38) | |
| Recipient location | | 0.011 |
| Home | Reference | |
| Inpatient | 1.08 (0.94-1.24) | |
| ICU | 1.28 (1.09-1.51) | |
| Recipient diabetes | 1.23 (1.09-1.38) | 0.001 |
| Recipient kidney disease | | 0.002 |
| Glomerular disease | Reference | |
| Diabetes | 1.17 (0.94-1.45) | |
| Hypertension | 1.19 (0.93-1.50) | |
| Polycystic kidney disease | 0.63 (0.45-0.89) | |

| | | |
|----------------------------|------------------|--------|
| Hepatorenal syndrome | 0.96 (0.77-1.20) | |
| Other | 1.11 (0.91-1.35) | |
| Female donor sex | 1.00 (0.90-1.11) | 0.999 |
| Kidney graft CIT, per hour | 1.01 (1.00-1.01) | 0.043 |
| Split liver | 1.10 (0.69-1.35) | 0.692 |
| Share type | | 0.019 |
| Local | Reference | |
| Regional | 1.19 (1.04-1.35) | |
| National | 1.26 (0.90-1.75) | |
| Transplant era | | <0.001 |
| 2005-2009 | Reference | |
| 2010-2014 | 0.79 (0.70-0.90) | |
| 2015-2020 | 0.73 (0.62-0.85) | |

Supplemental Table 8: Multivariable Cox proportional hazards model evaluating center MP use as a predictor of kidney graft survival (N=5,930)

| | Covariate-adjusted HR for graft survival (95% CI) | p-value |
|--|---|--------------|
| Center MP use, per 10% increase | 1.00 (0.98-1.03) | 0.851 |
| Recipient female sex | 0.93 (0.76-0.94) | 0.172 |
| Recipient age, per year | 1.01 (1.00-1.02) | 0.001 |
| Recipient race/ethnicity | | <0.001 |
| White | Reference | |
| Black | 1.19 (1.06-1.35) | |
| Hispanic | 0.83 (0.71-0.97) | |
| Asian | 0.98 (0.74-1.29) | |
| Other | 0.54 (0.33-0.88) | |
| Native MELD at LT, per point | 1.00 (0.99-1.01) | 0.444 |
| Kidney disease severity | | 0.006 |
| On dialysis | Reference | |
| eGFR <30mL/min/1.73m ² * | 0.85 (0.76-0.94) | |
| eGFR ≥30mL/min/1.73m ² * | 0.82 (0.70-0.95) | |
| Ascites | | 0.230 |
| None | Reference | |
| Mild | 1.00 (0.87-1.15) | |
| Moderate-severe | 0.92 (0.80-1.05) | |
| Encephalopathy | | 0.132 |
| None | Reference | |
| Grade 1-2 | 1.04 (0.90-1.20) | |
| Grade 3-4 | 1.20 (1.00-1.45) | |
| Recipient location | | 0.055 |
| Home | Reference | |
| Inpatient | 1.08 (0.94-1.23) | |
| ICU | 1.26 (1.04-1.52) | |
| Recipient diabetes | 1.24 (1.11-1.38) | <0.001 |
| Recipient kidney disease | | <0.001 |
| Glomerular disease | Reference | |
| Diabetes | 1.17 (0.97-1.41) | |
| Hypertension | 1.22 (0.95-1.58) | |
| Polycystic kidney disease | 0.63 (0.48-0.85) | |
| Hepatorenal syndrome | 0.95 (0.75-1.20) | |
| Other | 1.10 (0.92-1.33) | |
| Donor age, per year | 1.01 (1.01-1.02) | <0.001 |
| Female donor sex | 1.03 (0.94-1.14) | 0.513 |
| Donor race/ethnicity | | 0.064 |
| White | Reference | |
| Black | 1.20 (1.04-1.37) | |
| Hispanic | 1.07 (0.94-1.22) | |
| Asian/other | 1.10 (0.83-1.46) | |
| Donor hypertension | 1.16 (1.01-1.34) | 0.036 |
| Donor diabetes | 1.05 (0.83-1.32) | 0.700 |
| DCD donor | 1.50 (1.21-1.85) | <0.001 |
| Kidney graft CIT, per hour | 1.00 (1.00-1.01) | 0.019 |

| | | |
|---------------------------------------|------------------|-------|
| Split liver | 1.16 (0.70-1.90) | 0.569 |
| Share type | | 0.004 |
| Local | Reference | |
| Regional | 1.21 (1.05-1.38) | |
| National | 1.41 (1.03-1.93) | |
| Donor HCV Ab positive | 0.93 (0.74-1.17) | 0.516 |
| Donor terminal creatinine, per 1mg/dL | 1.03 (0.87-1.09) | 0.319 |
| Donor BMI, per kg/m ² | 1.00 (0.99-1.01) | 0.582 |
| Donor cause of death | | 0.265 |
| Anoxia | Reference | |
| CVA | 1.01 (0.88-1.16) | |
| Head trauma | 0.96 (0.83-1.10) | |
| CNS tumor | 1.31 (0.69-2.49) | |
| Other | 0.76 (0.55-1.05) | |
| Transplant era | | 0.009 |
| 2005-2009 | Reference | |
| 2010-2014 | 0.80 (0.69-0.93) | |
| 2015-2020 | 0.76 (0.62-0.94) | |